Clinical trial NCT04331613: Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS
Official title: Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: COVID-19
Acute Respiratory Distress Syndrome
Virus; Pneumonia
Acute Lung Injury
Keywords: CAStem
Stem Cells
Cell Therapy
IMRCs
Lead sponsor: Chinese Academy of Sciences
Sponsor class: OTHER_GOV
Collaborators: name: Beijing YouAn Hospital
First posted: 2020-04-02
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase1/2, open label, dose escalation, safety and early efficacy study of CAStem for the treatment of severe COVID-19 associated with or without ARDS.

Detailed description: CAStem is an injectable product composed of immunity- and matrix-regulatory cells (IMRCs), also named M cells, differentiated from clinical-grade human embryonic stem cells (hESCs) will be expanded, harvested, and formulated at a concentration of 50 x 10\^6 cells/mL. CAStem will be cryopreserved and transported to clinical site using liquid nitrogen vapor shipping vessels (\< -150ºC). Prior to injection, CAStem will be thawed to liquefy quickly, and then reconstituted in normal saline.In the present study, the intravenous infusion dose of CAStem will be 3, 5 or 10 million cells/kg.

Eligibility criteria: Inclusion criteria:

1. Chinese patients, aged 18 to 70 years old, males or females;
2. Diagnosis of COVID-19, and confirm by chest CT scan;
3. According to the diagnosis and treatment plan for the novel coronavirus disease (COVID-19) (trial version 5) issued by the National Health Commission (NHC) on the diagnostic criteria for severe or critical ill COVID-19 patients including the patients with acute respiratory distress syndrome (ARDS), the specific diagnostic criteria are:

   Severely ill patients should meet all of the following:
   * 1. Respiratory distress, RR ≥ 30 times/min.
   * 2. In a resting state (without oxygen supplementation), oxygen saturation ≤ 93%.
   * 3. Partial arterial oxygen pressure (PaO2) / oxygen absorption concentration (FiO2) ≤ 300 mmHg (1 mmHg = 0.133 kpa). High altitude (above sea level 1000 m) area should be calibrated for PaO2/FiO2 according to the following method: PaO2/FiO2\*\[atmospheric pressure (mmHg)/760\]. Patients with obvious progress in lung lesions by chest CT within 24-48 hours should be counted as the server cases.

   Critically ill patients should meet one of the following :
   * 1. Respiratory failure, the mechanical ventilation required.
   * 2. Shock.
   * 3. Associated with other organ failure, ICU needed for monitoring and management.
4. Voluntarily participate in the study, agree to comply with the requirements of the clinical trial protocol, and sign the informed consent.

Exclusion criteria:

1. Patients with a history of transplantation of cells or organ(s).
2. Patients with a history of malignancy or pathology indicating severe atypical hyperplasia.
3. Patients without life expectancy of 48 hours.
4. Patients with moderate to severe liver failure (Childs Pugh scores \> 12).
5. Patients with cardiogenic pulmonary edema.
6. Patients with a history of deep vein thrombosis or pulmonary embolism within 3 months before the screening.
7. Patients with severe chronic pulmonary diseases, including but not restricted to the patients with WHO grade III or IV pulmonary hypertension or those with chronic pulmonary diseases requiring long-term oxygen therapy.
8. Patients with unstable ventricular tachycardia or ventricular fibrillation.
9. Patients with poor coagulation, severe bleeding tendency or active bleeding at present.
10. Patients with serious dysfunction involved in the major organs or systems (liver, kidney, gastrointestinal, cardiovascular, blood coagulation, central system, etc.) besides the respiratory system are not suitable to participate in the present study.
11. Patients with a history of severe conditions in any organs or systems.
12. Patients who are unable to accept other invasive rescue except cardiopulmonary resuscitation.
13. Patients who are allergic to the main active ingredients or excipients of the investigational drug.
14. Women who are pregnant, breastfeeding or planning to become pregnant during the study period. Woman of childbearing age who is not willing to use appropriate contraceptive methods through the completion of the clinical study.
15. Patients whose participation is considered to bring significant risks to the present clinical study, cause confusion in analysis, or significantly interfere with the clinical research results.

Primary outcomes:
measure: Adverse reaction (AE) and severe adverse reaction (SAE)
timeFrame: Within 28 days after treatment
measure: Changes of lung imaging examinations
timeFrame: Within 28 days after treatment
Secondary outcomes:
measure: Time to SARS-CoV-2 RT-PCR negative
timeFrame: Within 28 days after treatment
measure: Duration of fever (Celsius)
timeFrame: Within 28 days after treatment
measure: Changes of blood oxygen (%)
timeFrame: Within 28 days after treatment
measure: Rate of all-cause mortality within 28 days
timeFrame: Within 28 days after treatment
measure: Lymphocyte count (*10^9/L)
timeFrame: Within 28 days after treatment
measure: Alanine aminotransferase (U/L)
timeFrame: Within 28 days after treatment
measure: Creatinine (umol/L)
timeFrame: Within 28 days after treatment
measure: Creatine kinase (U/L)
timeFrame: Within 28 days after treatment
measure: C-reactive protein (mg/L)
timeFrame: Within 28 days after treatment
measure: Procalcitonin (ng/L)
timeFrame: Within 28 days after treatment
measure: Lactate (mmol/L)
timeFrame: Within 28 days after treatment
measure: IL-1beta (pg/mL)
timeFrame: Within 28 days after treatment
measure: IL-2 (pg/mL)
timeFrame: Within 28 days after treatment
measure: IL-6 (pg/mL)
timeFrame: Within 28 days after treatment
measure: IL-8 (pg/mL)
timeFrame: Within 28 days after treatment
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing YouAn Hospital, Capital Medical University
state: Beijing, China
Study officials:
affiliation: Institute of Zoology, Chinese Academy of Sciences
name: Zhou Qi, Doctor
role: PRINCIPAL_INVESTIGATOR
References: